Literature DB >> 16554497

An innovative approach to involve patients in measuring treatment effects in drug trials.

Hanna Kaduszkiewicz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16554497      PMCID： PMC1421449          DOI： 10.1503/cmaj.060261

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  AD2000: donepezil in Alzheimer's disease.

Authors:  Lon S Schneider
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

Review 2.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Authors:  Hanna Kaduszkiewicz; Thomas Zimmermann; Hans-Peter Beck-Bornholdt; Hendrik van den Bussche
Journal:  BMJ       Date:  2005-08-06

3.  Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

Authors:  Kenneth Rockwood; Sherri Fay; Xiaowei Song; Chris MacKnight; Mary Gorman
Journal:  CMAJ       Date:  2006-03-22       Impact factor: 8.262
  3 in total
  1 in total

1.  The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.

Authors:  Kenneth Rockwood; Sherri Fay; Mary Gorman; Daniel Carver; Janice E Graham
Journal:  BMC Neurol       Date:  2007-08-30       Impact factor: 2.474
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.